Clinical Trial

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

Study acronym: ATTR-CM
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-15.
Trial Details
NCT Number NCT07306949
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Transthyretin-type Cardiac Amyloidosis
Enrollment 200 participants
Start Date 2025-10-01
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-07